The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | The DLL3-targeting BiTE, tarlatamab, for the treatment of SCLC
Delta-like ligand 3 (DLL3) is overexpressed in the majority of small cell lung cancer (SCLC). Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, provides an overview of a Phase I dose exploration study (NCT03319940) investigating tarlatamab, a half-life extended bispecific T cell engager (BiTE) which binds to DLL3 and CD3, thereby inducing T-cell mediated tumor lysis. Tarlatamab demonstrated a manageable safety profile and encouraging efficacy in a heavily pretreated SCLC population. Prof. Borghaei emphasizes the need for additional studies to identify the optimal approach to use tarlatamab in this difficult-to-treat patient population. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
